Fig. 2

Pre-transplant α-diversity and β-diversity associated with liver disease etiology and severity. a Shannon and Chao α-diversity and b UniFrac β-diversity indices stratified by primary indication for LT (AIH n = 7; ARLD n = 7; HBV n = 8; HCV n = 37; NAFLD n = 14). c, d α-diversity and UniFrac β-diversity stratified by high vs. low MELD score at the time of LT (> 18 (n = 43) vs. ≤ 18 (n = 40)). e, f α-diversity and UniFrac β-diversity stratified by CTP class at the time of LT (a (n = 16) vs. b (n = 24) vs. c (n = 43)). a, c, e α-Diversity boxplots reflect median (horizontal center line), 25th and 75th percentile values (bottom and top bounds of boxes), and ranges (bottom and top of whiskers) for each category. Each panel shows P-values for univariate linear regression (see Table 2) as follows: ⁺ P < 0.1; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. b, d, f PERMANOVA P-values and pseudo-F-statistic values calculated using UniFrac β-diversity distances are shown. LT liver transplant, AIH autoimmune hepatitis, ARLD alcohol-related liver disease, BILIARY biliary-related etiologies, HBV hepatitis B virus, HCV hepatitis C virus, NAFLD nonalcoholic fatty liver disease, PCLD polycystic liver/kidney disease, MELD model for end-stage liver disease, CTP Child–Turcotte–Pugh. Source data are provided as a Source Data file